Otava has extensive experience in the synthesis of highly valuable products for biotech and pharmaceutical applications around the world
Otava sells novel CK2 inhibitors developed by its scientists as well as potent and selective inhibitors of IKK-andepsilon, Sirt1, Sirt2, Stat3, JNK3, GSK-3, CDK9, HDAC, HIF-1, eEF-2 kinase, CFTR chloride channel and more.
These compounds are available in milligram and gram quantities.
It also sells intermediates on route to the synthesis of these compounds.
Custom and bulk quotes for final products and intermediates are available too.
See and download a full list of noteworthy compounds from its website.
Otava helps companies around the world to advance their projects, by synthesising starting materials, intermediates, and/or final products, advanced intermediates in drug synthesis, and combinatorial chemistry templates and building blocks.
Otava's main products and services are compound libraries (about 500,000 in-stock compounds), focused libraries (kinases, proteases, etc), kinase ProHit compound sets, molecular modelling services, custom synthesis on the base of rare scaffolds, anticancer compounds, and contract research.
